1. Hamblin T.J. Autoimmune complications of chronic lymphocytic leukemia // Semin. Oncol. 2006. Vol. 33, N 2. P. 230–239.
2. Hodgson K. et al. Autoimmune cytopenia in chronic lymphocytic leukaemia: diagnosis and treatment // Br. J. Haematol. 2011. Vol. 154, N 1. P. 14–22.
3. Diehl L.F., Ketchum L.H. Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia // Semin. Oncol. 1998. Vol. 25, N 1. P. 80–97.
4. Ebbe S., Wittels B., Dameshek W. Autoimmune thrombocytopenic purpura («ITP» type) with chronic lymphocytic leukemia // Blood. 1962. Vol. 19. P. 23–37.
5. Hallek M. et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL // Blood. 2018. Vol. 131, N 25. P. 2745–2760.
6. Visco C., Rodeghiero F. Immune thrombocytopenia in lymphoproliferative disorders // Hematol. Oncol. Clin. North Am. 2009. Vol. 23, N 6. P. 1261–1274.
7. Zent C.S. et al. Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis // Leuk. Lymphoma. 2009. Vol. 50, N 8. P. 1261–1268.
8. Pettitt A.R. et al. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial // J. Clin. Oncol. 2012. Vol. 30, N 14. P. 1647–1655.
9. Mauro F.R. et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features // Blood. 2000. Vol. 95, N 9. P. 2786–2792.
10. Zent C.S. et al. The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma // Br. J. Haematol. 2008. Vol. 141, N 5. P. 615–621.
11. Moreno C. et al. Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance // Blood. 2010. Vol. 116, N 23. P. 4771–4776.
12. Borthakur G. et al. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab – incidence and predictors // Br. J. Haematol. 2007. Vol. 136, N 6. P. 800–805.
13. Dearden C. et al. The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia // Blood. 2008. Vol. 111, N 4. P. 1820–1826.
14. Jung M., Rice L. Unusual autoimmune nonhematologic complications in chronic lymphocytic leukemia // Clin. Lymphoma Myeloma Leuk. 2011. Vol. 11. P. S10–S13.
15. Alattar M.L. et al. Bleeding diathesis associated with acquired von Willebrand syndrome in three patients with chronic lymphocytic leukemia // Leuk. Lymphoma. 2015. Vol. 56, N 12. P. 3452–3454.
16. Tandra P. et al. Autoimmune cytopenias in chronic lymphocytic leukemia, facts and myths // Mediterr. J. Hematol. Infect. Dis. 2013. Vol. 5, N 1. Article ID e2013068.
17. KonichiDias R.L. et al. Paraneoplastic pemphigus associated with chronic lymphocytic leukemia: a case report // J. Med. Case Rep. 2018. Vol. 12, N 1. P. 252.
18. Cao L. et al. Chronic lymphocytic leukemiaassociated paraneoplastic pemphigus: potential cause and therapeutic strategies // Sci. Rep. 2020. Vol. 10, N 1. Article ID 16357.
19. Abdulkareem A. et al. Refractory abdominal pain in a patient with chronic lymphocytic leukemia: be wary of acquired angioedema due to C1 esterase inhibitor deficiency // Case Rep. Hematol. 2018. Vol. 2018. Article ID 7809535.
20. Mohyuddin G., Rabinowitz I. A patient with chronic lymphocytic leukemia and acquired angioedema: correlation of clinical and biochemical response to CLL therapy // Ecancermedicalscience. 2013. Vol. 7. P. 292.
21. Wanchoo R. et al. Renal involvement in chronic lymphocytic leukemia // Clin. Kidney J., 2018. Vol. 11, N 5. P. 670–680.
22. Beaume A. et al. High incidence of serum monoclonal Igs detected by a sensitive immunoblotting technique in Bcell chronic lymphocytic leukemia // Blood. 1994. Vol. 84, N 4. P. 1216–1219.
23. Stevenson F.K. et al. Extracellular idiotypic immunoglobulin arising from human leukemic B lymphocytes // J. Exp. Med. 1980. Vol. 152, N 6. P. 1484–1496.
24. Bröker B.M. et al. Chronic lymphocytic leukemia (CLL) cells secrete multispecific autoantibodies // J. Autoimmun. 1988. Vol. 1, N 5. P. 469–481.
25. Galletti J. et al. Chronic lymphocytic leukemia cells bind and present the erythrocyte protein band 3: possible role as initiators of autoimmune hemolytic anemia // J. Immunol. 2008. Vol. 181, N 5. P. 3674–3683.
26. Hall A.M. et al. Rh autoantigen presentation to helper T cells in chronic lymphocytic leukemia by malignant B cells // Blood. 2005. Vol. 105, N 5. P. 2007–2015.
27. Strati P., CaligarisCappio F. A matter of debate in chronic lymphocytic leukemia: is the occurrence of autoimmune disorders an indicator of chronic lymphocytic leukemia therapy? // Curr. Opin. Oncol. 2011. Vol. 23, N 5. P. 455–460.
28. Ward F.J. et al. Clonal regulatory T cells specific for a red blood cell autoantigen in human autoimmune hemolytic anemia // Blood. 2008. Vol. 111, N 2. P. 680–687.
29. Gorgun G. et al. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells // J. Clin. Invest. 2005. Vol. 115, N 7. P. 1797–1805.
30. Beyer M. et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine // Blood. 2005. Vol. 106, N 6. P. 2018–2025.
31. Wright G.P., Ehrenstein M.R., Stauss H.J. Regulatory Tcell adoptive immunotherapy: potential for treatment of autoimmunity // Expert Rev. Clin. Immunol. 2011. Vol. 7, N 2. P. 213–225.